Can-Fite BioPharma Ltd.
CANF
$1.23
-$0.03-2.38%
AMEX
| 12/31/2024 | 06/30/2024 | 12/31/2023 | 09/30/2022 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 2.25% | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | 2.25% | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | 2.25% | |
| SG&A Expenses | -- | -- | -- | -2.07% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | -- | -- | -- | -9.93% | |
| Operating Income | -- | -- | -- | 10.72% | |
| Income Before Tax | -- | -- | -- | 7.07% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -- | -- | -- | 7.07% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -- | -- | -- | 7.07% | |
| EBIT | -- | -- | -- | 10.72% | |
| EBITDA | -- | -- | -- | 10.74% | |
| EPS Basic | -- | -- | -- | 21.58% | |
| Normalized Basic EPS | -- | -- | -- | 41.73% | |
| EPS Diluted | -- | -- | -- | 21.58% | |
| Normalized Diluted EPS | -- | -- | -- | 41.73% | |
| Average Basic Shares Outstanding | -- | -- | -- | 54.71% | |
| Average Diluted Shares Outstanding | -- | -- | -- | 54.71% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |